Association between newly diagnosed hyperglycemia/diabetes mellitus, atherogenic index of plasma and obesity in post-COVID-19 syndrome patients
- PMID: 38001321
- DOI: 10.1007/s12020-023-03611-4
Association between newly diagnosed hyperglycemia/diabetes mellitus, atherogenic index of plasma and obesity in post-COVID-19 syndrome patients
Abstract
Purpose: The COVID-19 pandemic represents a great global concern and its associated morbidities. The goal of this study was to determine the incidence of newly diagnosed hyperglycemia and diabetes among COVID-19 survivors and to evaluate whether obesity and lipid profile have an effect on this group using the atherogenic index of plasma (AIP).
Methods: In the retrospective study, 511 adults with a previously diagnosed "Severe Acute Respiratory Syndrome Coronavirus 2" who admitted to COVID-19 follow-up outpatient clinic were evaluated. Data was collected on patient demographics, comorbidities, and some laboratory results. Logistic regression was used to estimate associated factors.
Results: Newly diagnosed type 2 diabetes mellitus (T2DM) was defined in 17 patients (3.32%), hyperglycemia in 86 patients (16.82%). The results of analysis were examined, gender, age, BMI and triglyceride variables were found to be significant risk factors together. Fasting blood glucose values of 22 out of 86 patients with hyperglycemia returned to normal after six months of follow-up. Undiagnosed-preexisting DM in 4 out of 17 patients diagnosed with T2DM at their first visit and in 7 out of 8 hyperglycemia patients diagnosed with T2DM at the end of six-month follow-up.
Conclusion: COVID-19, may directly/indirectly, predispose to hyperglycemia. Obesity and hyperlipidemia are risk factors for newly diagnosed T2DM/hyperglycemia in post-COVID-19 syndrome patients. Since that some metabolic variables were found to be significantly higher in the group with high AIP values, we suggest that AIP might be used as a reference to predict the development of obesity and T2DM.
Keywords: COVID-19; Hyperglycemia; Obesity; Post-acute-COVID-19 syndromes; Type 2 diabetes mellitus.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- J.B. Soriano, S. Murthy, J.C. Marshall, P. Relan, J.V. Diaz; WHO Clinical Case Definition Working Group on Post-COVID-19 Condition, A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 22(4), e102–e107 (2022). https://doi.org/10.1016/S1473-3099(21)00703-9 - DOI - PubMed
-
- A.V. Raveendran, A. Misra, Post COVID-19 syndrome (“Long COVID”) and diabetes: challenges in diagnosis and management. Diabetes Metab. Syndr. 15(5), 102235 (2021). https://doi.org/10.1016/j.dsx.2021.102235 - DOI - PubMed - PMC
-
- J. Harding, S.A. Oviedo, M.K. Ali, I. Ofotokun, J.C. Gander, S.A. Patel et al. The bidirectional association between diabetes and Long-COVID-19-A systemic review. Diabetes Res Clin Prac 195, 110202 (2023). https://doi.org/10.1016/j.diabres.2022.110202 - DOI
-
- A. Ghosh, R.M. Anjana, C.S. Shanthi Rani, S. Jeba Rani, R. Gupta, A. Jha et al. Glycemic parameters in patients with new-onset diabetes during COVID-19 pandemic are more severe than in patients with new-onset diabetes before the pandemic: NOD COVID India Study. Diabetes Metab. Syndr. 15(1), 215–220 (2021). https://doi.org/10.1016/j.dsx.2020.12.033 - DOI - PubMed
-
- A.A. Metwally, P. Mehta, B.S. Johnson, A. Nagarjuna, M.P. Synder, COVID-19-induced new onset diabetes: trends and technologies. Diabetes 70(12), 2733–2744 (2021). https://doi.org/10.23337/dbi21-0029 - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
